J. Goldman & CO LP Vaxcyte, Inc. Transaction History

J. Goldman & CO LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$60.06 - $78.77 $162,162 - $212,679	2,700 New	2,700 $203,000
Q4 2023 Feb 14, 2024	BUY	$45.35 - $63.41 $408,603 - $571,324	9,010 Added 103.75%	17,694 $1.11 Million
Q3 2023 Nov 14, 2023	SELL	$46.0 - $53.1 $16,882 - $19,487	-367 Reduced 4.05%	8,684 $442,000
Q2 2023 Aug 14, 2023	BUY	$34.66 - $54.07 $7,971 - $12,436	230 Added 2.61%	9,051 $452,000
Q1 2023 May 15, 2023	SELL	$36.27 - $47.2 $1.02 Million - $1.33 Million	-28,219 Reduced 76.19%	8,821 $330,000
Q4 2022 Feb 14, 2023	BUY	$20.58 - $47.95 $326,645 - $761,062	15,872 Added 74.98%	37,040 $1.78 Million
Q3 2022 Nov 14, 2022	BUY	$21.69 - $28.53 $459,133 - $603,923	21,168 New	21,168 $508,000

359

124M

772K

430K

Ticker PCVX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,315,100
Market Cap $5.19B
Description
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...

Get notified when there are updates to the investment portfolio of J. Goldman & CO LP, based on Form 13F filings with the SEC.

Stay updated on J. Goldman & CO LP with notifications on news.